SSG
SANA icon

Summit Securities Group’s Sana Biotechnology SANA Stock Holding History

Summit Securities Group’s Portfolio SANA Stock Details SANA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-450
Closed -$756 – 1392
2025
Q1 		$756 Buy
+450
New +$1.26K ﹤0.01% 707
2024
Q4 		– Sell
-464
Closed -$2K – 861
2024
Q3 		$2K Buy
+464
New +$2.44K ﹤0.01% 490

Other funds holding SANA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MG
Marex Group London $15.8B AUM 31.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Summit Securities Group's SANA Position: Q2 2025 in Review

Summit Securities Group sold out of Sana Biotechnology (SANA) in Q2 2025, closing a stake of 450 shares — an estimated $756 sold.

Summit Securities Group first reported a position in SANA in Q3 2024 and held it in 2 quarters. The position peaked at $2K in Q3 2024. 155 funds tracked by Wall St. Rank hold SANA as of Q2 2025.

  • Summit Securities Group reported no remaining Sana Biotechnology position as of Q2 2025 after selling out during the quarter.
  • Summit Securities Group sold 450 Sana Biotechnology shares in Q2 2025, an estimated $756.
  • Summit Securities Group first reported a position in Sana Biotechnology in Q3 2024 and held it in 2 quarters.
  • Summit Securities Group's Sana Biotechnology position peaked at $2K in Q3 2024.
  • 155 funds tracked by Wall St. Rank held Sana Biotechnology as of Q2 2025.

Based on Summit Securities Group's 13F filing for Q2 2025, filed 12 Aug 2025.